SCHEMBL3740233

SCHEMBL3740233

Cc1ccc(-c2ccc(F)cc2CC(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.57
FFAR1 O14842 3/20 0.57
PPARG P37231 6/20 0.50
PTGDR2 Q9Y5Y4 3/20 0.45
PTGS1 P23219 1/20 0.44
TSHR P16473 1/20 0.43
RXRA P19793 1/20 0.43
SRC P12931 1/20 0.43
AGBL2 Q5U5Z8 1/20 0.43
ABCB1 P08183 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749563 0.90 TSHR (0.47) FFAR4FFAR1PPARGPTGDR2PTGS1
SCHEMBL3731501 0.85 FFAR1 (0.54) FFAR4FFAR1PPARGPTGDR2PTGS1
SCHEMBL3736882 0.84 AKR1C3 (0.49) FFAR4FFAR1PPARGPTGDR2TSHR
SCHEMBL3749551 0.84 HSD17B10 (0.54) FFAR4FFAR1PPARGPTGDR2PTGS1
SCHEMBL9890672 0.82 PSEN1 (0.61) FFAR4FFAR1PPARGPTGDR2RXRA
SCHEMBL17450543 0.82 FFAR4 (0.50) FFAR4FFAR1PTGS1ABCB1
SCHEMBL3741185 0.81 PTGDR2 (0.49) FFAR4FFAR1PTGDR2TSHRAGBL2
SCHEMBL3741692 0.81 FFAR1 (0.57) FFAR4FFAR1PTGDR2PTGS1SRC
SCHEMBL9890677 0.81 PTGS2 (0.47) PPARGPTGDR2PTGS1SRC
SCHEMBL9890671 0.79 PTGDR2 (0.50) FFAR4FFAR1PPARGPTGDR2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817031-B1 CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY MERCK PATENT GMBH (DE) 2014-05-21 EP claimed
US-7829721-B2 Specific caspase-10 inhibitors MERCK PATENT GMBH (DE) 2010-11-09 US claimed
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors MERCK PATENT GESELLSCHAFT (DE) 2008-10-16 US claimed
EP-1817031-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS Merck Patent GmbH (DE) 2007-08-15 EP claimed
WO-2006058592-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS MERCK PATENT GMBH (DE) 2006-06-08 WO claimed
EP-1817031-B1 CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY MERCK PATENT GMBH (DE) 2014-05-21 EP disclosed
US-7829721-B2 Specific caspase-10 inhibitors MERCK PATENT GMBH (DE) 2010-11-09 US disclosed
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors MERCK PATENT GESELLSCHAFT (DE) 2008-10-16 US disclosed
EP-1817031-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS Merck Patent GmbH (DE) 2007-08-15 EP disclosed
WO-2006058592-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS MERCK PATENT GMBH (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors CASP10, CASP1, CASP5 FFAR4 860/4885FFAR1 624/4885PPARG 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.